Development of small hepatocellular carcinoma in a patient with chronic hepatitis C after 77 months of a sustained and complete response to interferon therapy

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue 11, 2002, Pages 1229-1235

  Yamaura, Takahiro ^a   Matsumoto, Akihiro ^a   Rokuhara, Akinori ^a   Ichijo, Tetuya ^a   Tanaka, Eiji ^a   Hanazaki, Kazuhiro ^a   Kajikawa, Shoji ^a   Kiyosawa, Kendo ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Complete response; Hepatitis C virus; Hepatocellular carcinoma; Interferon

Indexed keywords

ALPHA2A INTERFERON; AMINOTRANSFERASE; VIRUS RNA;

AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CASE REPORT; DISEASE COURSE; FEMALE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LIVER BIOPSY; LIVER CELL CARCINOMA; PARTIAL HEPATECTOMY; PHYSICAL EXAMINATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0036912478     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2002.02710.x     Document Type: Article

References (34)

1. Kiyosawa K, Sodeyama T, Tanaka E et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990; 12: 671-5.
2. Bruix J, Barrera JM, Calvet XG et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepa-tocellular carcinoma and hepatic cirrhosis. Lancet 1989; ii: 1004-6.
3. Colombo M, Kou G, Choo GL et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989; ii: 1006-8.
4. Saito I, Miyamura T, Ohbayashi A et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc. Natl Acad. Sci. USA 1990; 87: 6547-9.
5. Nishioka K, Watanabe J, Furuta S et al. A high prevalance of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer 1991; 67: 429-33.
6. Kobayashi M, Tanake E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. The natural course of chronic hepatitis C. A comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 1996; 23: 695-9.
7. Sharara AI, Hunt CM, Hamilton JD. Hepatitis C. Ann. Intern. Med. 1996; 125: 658-68.
8. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: A preliminary report. N. Engl. J. Med. 1986; 315: 1575-8.
9. Yoshioka K, Kakumu S, Wakita T et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-α therapy: Relationship to genotypes of hepatitis C virus. J. Hepatol. 1992; 16: 293-9.
10. Nishiguchi S, Kuroki T, Nakatani S et al. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
11. Mazzella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J. Hepatol. 1996; 24: 141-7.
12. International Interferon-α Hepatocellular Carcinoma Study Group. Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: A retrospective study. Lancet 1998; 351: 1535-9.
13. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. J. Hepatol. 1998; 27: 1394-402.
14. Imai Y, Kawata S, Tamura S et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann. Intern. Med. 1998; 129: 94-9.
15. Miyajima I, Sata M, Kumashiro R et al. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment. Oncol. Report 1998; 5: 201-4.
16. Tanaka K, Sata M, Uchimura Y, Suzuki H, Tanikawa K. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: Does IFN prevent development of hepatocellular carcinoma. Oncol. Rep. 1998; 5: 205-8.
17. Okamoto H, Sugiyama Y, Okada S et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J. Gen. Virol. 1992; 73: 673-9.
18. Ichida F, Tsuji T, Omata M et al. New Inuyama classification: New criteria for histological assessment of chronic hepatitis. Int. Hepatol. Commun. 1996; 6: 112-19.
19. Sato A, Kato Y, Nakata K et al. Relationship between sustained elevation of serum alanine aminotransferase and progression from cirrhosis to hepatocellular carcinoma: Comparison in patients with hepatitis B virus- and hepatitis C virus-associated cirrhosis. J. Gastroenterol. Hepatol. 1996; 11: 944-8.
20. Tarao K, Takemiya S, Tamai S et al. Relationship between the recurrence of hepatocellular carcinoma (HCC) and serum alanine aminotransferase levels in hepatectomized patients with hepatitis C virus-associated cirrhosis and HCC. Cancer 1997; 79: 688-94.
21. Omagari K, Ikuno N, Imanishi T et al. Interferon-alpha 2a treatment for chronic hepatitis C without cirrhosis and its effects on incidence of hepatocellular carcinoma. J. Infect. Chemother. 1998; 4: 209-13.
22. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. J. Hepatol. 1995; 201: 650-5.
23. Koretz RL. Interferon and hepatocellular carcinoma. Lancet 1996; 347: 194.
24. Andreone P, Cursaro C, Gramenzi A, Trevisani F, Gasbarrini G, Bernardi M. Interferon and hepatocellular carcinoma. Lancet 1996; 347: 195.
25. Bruno S, Silini E, Crosignani A et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. J. Hepatol. 1997; 25: 754-8.
26. Fattovich G, Giustina G, Degos F et al. Effectiveness of interferon alpha on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. J. Hepatol. 1997; 27: 201-5.
27. Kuroki T, Nishiguchi S, Nakatani S. Reply: Interferon and hepatocellular carcinoma. Lancet 1996; 347: 194-5.
28. Hirashima N, Mizokami M, Orito E et al. Development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-α. J. Gastroenterol. Hepatol. 1996; 11: 955-8.
29. Yamaguchi K, Omagari K, Kinoshita H et al. Development of hepatocellular carcinoma in a patient with chronic hepatitis C after 6 years of a sustained and complete response to IFN-α. J. Clin. Gastroenterol. 1999; 29: 207-9.
30. Sugiura N, Sakai Y, Ebara M et al. Detection of hepato-cellular carcinoma after interferon therapy for chronic hepatitis C. Clinical study of 26 cases. J. Gastroenterol. Hepatol. 1996; 11: 535-9.
31. Tamori A, Kuroki T, Nishiguchi S et al. Case of small hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus. Hepatogastroenterology 1996; 43: 1079-83.
32. Sugo H, Kitayama N, Iwata T et al. Development of hepa-tocellular carcinoma in a patient with chronic hepatitis C after a complete response to interferon therapy. Acta Hepatol. Jpn. 2000; 41: 195-8.
33. Okamura K, Yamazaki K, Ohmura T, Sato T, Karino Y, Toyoda N. A resected case of hepatocellular carcinoma with sustained response to interferon for five years. Acta Hepatol. Jpn. 2000; 41: 43-7.
34. Sheu JC, Sung JL, Chen DS et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 259-66.